Results 1 to 10 of about 41,474 (289)

Purification of yeast isocitrate dehydrogenase [PDF]

Biochemical Journal, 1972
The NAD-linked isocitrate dehydrogenase from baker's yeast was purified to homogeneity (as judged by gel filtration and polyacrylamide-gel electrophoresis) with an overall yield of 50% by using dilute solutions of the allosteric effector (AMP) to elute the enzyme specifically from CM-cellulose.
John Illingworth
openalex   +4 more sources

Mitochondrial Isocitrate Dehydrogenases from Yeast [PDF]

Journal of Biological Chemistry, 1966
Abstract A polarographic technique suitable for kinetic studies of either isolated or bound pyridine nucleotide-linked dehydrogenases was used to investigate the isocitrate dehydrogenases of yeast mitochondria. Intact mitochondria were found to contain both triphosphopyridine nucleotide- and diphosphopyridine nucleotide-linked isocitrate dehydrogenases
Carl Bernofsky, Merton Utter
openalex   +3 more sources

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics

Frontiers in Oncology, 2019
The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations across multiple cancer types including both solid and hematologic malignancies has revolutionized our understanding of oncogenesis in these malignancies and the ...
Danielle Golub, Siddhant Dogra, Devin Bready   +2 more
exaly   +3 more sources

Isocitrate protects DJ-1 null dopaminergic cells from oxidative stress through NADP+-dependent isocitrate dehydrogenase (IDH) [PDF]

PLoS Genetics, 2017
DJ-1 is one of the causative genes for early onset familiar Parkinson's disease (PD) and is also considered to influence the pathogenesis of sporadic PD. DJ-1 has various physiological functions which converge on controlling intracellular reactive oxygen
Woongchang Yoon, Kyung Shin Kang, Hyongjong Koh   +2 more
exaly   +2 more sources

Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma. [PDF]

Oncologist
Abstract Background Patients with intrahepatic cholangiocarcinoma (ICC) are prone to recurrence and poor survival. Targeted therapy related to isocitrate dehydrogenase (IDH) is an extremely important treatment.
Xu S, Cao L, Chen R, Ye C, Li Q, Jiang Q, Yan F, Wan M, Zhang X, Ruan J.   +9 more
europepmc   +3 more sources

A real-world study of adverse drug reactions of two isocitrate dehydrogenase inhibitor based on the US FDA adverse event reporting system and VigiAccess databases [PDF]

Frontiers in Pharmacology
Background and objectivesIsocitrate dehydrogenase (IDH) inhibitor drugs (Enasidenib, Ivosidenib) restore normal metabolism and epigenetic regulation in cells, offering a precision-targeted therapeutic option for acute myeloid leukemia (AML) patients with
Mengmeng Peng, Mengmeng Peng, Qian Guo, Zihan Dang, Baiquan Zhang, Manjuan Li, Manjuan Li, Zixuan Wang, Zixuan Wang, Xuemian Lu, Xuemian Lu, Jie Lin   +11 more
doaj   +2 more sources

Isocitrate Dehydrogenase Inhibitors in Glioma: From Bench to Bedside [PDF]

Pharmaceuticals
Isocitrate dehydrogenase (IDH) mutant gliomas are a primary malignancy of the central nervous system (CNS) malignancies, most commonly affecting adults under the age of 55.
Merve Hazal Ser, Mason Webb, Anna Thomsen, Ugur Sener   +3 more
doaj   +2 more sources

Expression of IDH1, ATRX, p53 in Diagnosis of Gliomas as Per 2016 WHO Classification [PDF]

Journal of Clinical and Diagnostic Research, 2023
Introduction: The 2016 World Health Organisation (WHO) classification of tumours of the Central Nervous System (WHO CNS 2016 classification) is used to classify diffuse gliomas as astrocytoma, Oligodendroglioma (ODG), glioblastoma which are three ...
Lokesh Kumar, Manjiri Karandikar, NS Mani, RC Nimbargi   +3 more
doaj   +1 more source

Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas. [PDF]

PLoS ONE, 2015
Isocitrate dehydrogenase 1 gene mutations are found in most World Health Organization grade II and III gliomas and secondary glioblastomas. Isocitrate dehydrogenase 1 mutations are known to have prognostic value in high-grade gliomas.
Ming-Yang Li, Yin-Yan Wang, Jin-Quan Cai, Chuan-Bao Zhang, Kuan-Yu Wang, Wen Cheng, Yan-Wei Liu, Wei Zhang, Tao Jiang   +8 more
doaj   +1 more source

Pattern of Recurrence of Glioblastoma Versus Grade 4 IDH-Mutant Astrocytoma Following Chemoradiation: A Retrospective Matched-Cohort Analysis

Technology in Cancer Research & Treatment, 2022
Background and Purpose: To quantitatively compare the recurrence patterns of glioblastoma (isocitrate dehydrogenase-wild type) versus grade 4 isocitrate dehydrogenase-mutant astrocytoma (wild type isocitrate dehydrogenase and mutant isocitrate ...
James Stewart PhD, Arjun Sahgal MD, Aimee K M Chan MSc, Hany Soliman MD, Chia-Lin Tseng MD, Jay Detsky MD, PhD, Sten Myrehaug MD, Eshetu G Atenafu MSc, Ali Helmi MD, James Perry MD, Julia Keith MD, Mary Jane Lim-Fat MD, MSc, David G Munoz MD, MSc, Gelareh Zadeh MD, PhD, David B Shultz MD, PhD, Sunit Das MD, PhD, Catherine Coolens PhD, Paula Alcaide-Leon MD, Pejman Jabehdar Maralani MD   +18 more
doaj   +1 more source